CompletedPhase 4

Continuous Clopidogrel Dose Adjustment in Acute Coronary Syndrome Patients With High On-treatment Platelet Reactivity

Croatia87 participantsStarted 2012-02

Plain-language summary

The purpose of this study is to determine whether continuous clopidogrel dose adjustment targeted after platelet function testing improves outcomes during 12 months of follow-up in acute coronary syndrome patients treated with coronary artery stenting and with determined high platelet reactivity on clopidogrel.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * acute coronary syndrome patients treated with successful PCI * age 18-80 years * determined high on-treatment platelet reactivity Exclusion Criteria: * continuous postinterventional glycoprotein (GP) IIbIIIa receptor inhibitor infusion * thrombocytopenia (\<150x109/L) * significant renal insufficiency (creatinine\>200 µmol/L) * anemia (Htc\<30%) * hemorrhagic diathesis * history of intracranial bleeding or ischemic cerebrovascular insult 6 months before * major operation 6 weeks before * concomitant chronic anticoagulation therapy * age \<18 years and \>80 years

What they're measuring

clinical outcome - composite endpoint of total cardiovascular death, non-fatal myocardial infarction, target vessel revascularization and ischemic stroke

Timeframe: 12 months

Trial details

NCT IDNCT02096419

SponsorUniversity of Zagreb

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-12

View on ClinicalTrials.gov More Acute Coronary Syndrome trials